AzurRx

Researchers found abnormal levels of specific gut bacteria in patients with chronic fatigue syndrome, including those with and without irritable bowel syndrome. http://www.upi.com//Microbiome-imbalance-li/5871493218167/

$AZRX reports positive mid-stage data on lead product candidate MS1819: https://seekingalpha.com//3256816-azurrx-reports-positive-

A weekly guide to the goings-on in the #biopharma industry: http://www.biopharmadive.com//prescribed-reading-e/441538/

$AZRX Stocks Added to Investor Ideas Directory http://www.investorideas.com/n/2017/biotech/04281Stocks.asp

$AZRX shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm: https://rivesjournal.com/sell-side-perspectives-on-azurr//

$AZRX: Early results indicate that MS1819 exhibits a favorable safety profile. http://www.reuters.com//brief-azurrx-provides-update-on-ms

#Biopharma: what has changed and where does opportunity reside? https://www.lifescienceleader.com//with-repeal-and-replace

#Biopharma companies are more open than ever before to collaborating with their peers: http://www.biopharmadive.com//biopharma-partnershi/440914/

Update on the ongoing open-label Phase IIa trial of lead candidate MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis (CP). http://azurrx.com/news-events/press-releases/2017/97-

#Drugmakers face a turning point on pricing putting the focus where it belongs: http://ow.ly/SxyT30b9Mpb

$AZRX has demonstrated early efficacy and favorable safety profile in an ongoing phase IIa trial. http://ow.ly/VTQN30b8vQx

A rapidly growing field of study the #microbiome. http://ow.ly/KdQB30aVEW6